A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.

NCT01727141 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1042

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG: QVA149
DRUG: QAB149
DRUG: NVA237
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals